TY - JOUR
T1 - Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis
T2 - Role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment
AU - Testa, Roberto
AU - Testa, E.
AU - Giannini, E.
AU - Botta, F.
AU - Malfatti, F.
AU - Chiarbonello, B.
AU - Fumagalli, A.
AU - Polegato, S.
AU - Podesta, E.
AU - Romagnoli, P.
AU - Risso, D.
AU - Cittadini, G.
AU - De Caro, G.
PY - 2003/6/15
Y1 - 2003/6/15
N2 - Background: Trans-catheter arterial chemoembolisation (TACE) is the most common palliative treatment for hepatocellular carcinoma (HCC). The therapeutic options depend both on the characteristics of the tumour and on functional staging of the cirrhosis. Aim: To evaluate the effects of TACE on the survival of cirrhotic patients with HCC according to different staging systems [Okuda score, Cancer Liver Italian Program (CLIP) score, Model for End-stage Liver Disease (MELD) score] and in relation to the side-effects of TACE. Methods: Fifty cirrhotic patients, 36 CTP class A and 14 class B, underwent 106 TACE treatments with mitoxantrone. Survival at 12, 24, and 36 months was evaluated. Results: MELD at 12 months and CLIP at 24 months were identified as significant variables associated with survival. Combined cut-offs of CLIP and of MELD identified four subgroups of patients with different survivals, at 12. 24 and 36 months, respectively: CLIP ≥2 and MELD ≥10 (63%, 20% and 0%), CLIP
AB - Background: Trans-catheter arterial chemoembolisation (TACE) is the most common palliative treatment for hepatocellular carcinoma (HCC). The therapeutic options depend both on the characteristics of the tumour and on functional staging of the cirrhosis. Aim: To evaluate the effects of TACE on the survival of cirrhotic patients with HCC according to different staging systems [Okuda score, Cancer Liver Italian Program (CLIP) score, Model for End-stage Liver Disease (MELD) score] and in relation to the side-effects of TACE. Methods: Fifty cirrhotic patients, 36 CTP class A and 14 class B, underwent 106 TACE treatments with mitoxantrone. Survival at 12, 24, and 36 months was evaluated. Results: MELD at 12 months and CLIP at 24 months were identified as significant variables associated with survival. Combined cut-offs of CLIP and of MELD identified four subgroups of patients with different survivals, at 12. 24 and 36 months, respectively: CLIP ≥2 and MELD ≥10 (63%, 20% and 0%), CLIP
UR - http://www.scopus.com/inward/record.url?scp=0038235639&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038235639&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.2003.01647.x
DO - 10.1046/j.1365-2036.2003.01647.x
M3 - Article
C2 - 12823161
AN - SCOPUS:0038235639
VL - 17
SP - 1563
EP - 1569
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 12
ER -